Benitec Biopharma Limited (NASDAQ:BNTC) Receives Consensus Recommendation of "Moderate Buy" from Analysts
Market Beat·- Benitec Biopharma Limited has received a consensus recommendation of "Moderate Buy" from ten covering brokerages, with a 1 - year average price target of $24.80. - The company's stock opened at $13.48 with a market capitalization of $463.04 million, while institutional investors and hedge funds currently own 52.19% of the shares. - Benitec Biopharma is a clinical-stage biotechnology company that develops gene-silencing therapies utilizing its proprietary DNA-directed RNA interference platform.Microsoft Stock Forecast: MSFT May Break $570 as Azure Growth Holds at 40%
TradingKey·- Microsoft stock closed at $ 481.15 on August 21, 2026, with analysts setting a consensus price target of $ 569.56. - Reaching this $ 570 target depends on sustaining Azure 's growth rate above 40 % and successfully breaking through the $ 500 resistance level. - Strong Azure demand and accelerating Copilot adoption support a positive outlook, though short-term technical resistance and high capital expenditures remain key variables.10 Financials Stocks With Whale Alerts In Today’s Session
benzinga_article·- Benzinga's options activity scanner tracked whale transactions for 10 financial stocks during the session. - The reported data includes key trading details such as put or call types, trade sentiments, expiration dates, strike prices, and total trade values. - These highlighted market movements assist traders in discovering potential trading opportunities driven by large capital entities.